Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
NCT00320827 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2007-09-11
Summary
This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six weeks and possibly up to 12 weeks depending on response.
Conditions
Interventions
- DRUG
-
CS-1008 (humanized anti-DR5 antibody)
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06651229 ·Status: RECRUITING ·Phase: PHASE1
-
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
NCT05289687 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
NCT05944978 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
NCT00027872 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
NCT01677780 ·Status: COMPLETED ·Phase: PHASE1
-
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
NCT04018248 ·Status: COMPLETED ·Phase: PHASE1
-
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT05086315 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
NCT05367700 ·Status: RECRUITING ·Phase: PHASE1
-
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT02715011 ·Status: COMPLETED ·Phase: PHASE1
-
Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
NCT06570915 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
NCT05100303 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
NCT05272813 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT05687032 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
NCT05345938 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
NCT01120457 ·Status: COMPLETED ·Phase: PHASE1
-
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
NCT03594955 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
NCT01880437 ·Status: TERMINATED ·Phase: PHASE2
-
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
NCT05858814 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
NCT01435720 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT05654779 ·Status: TERMINATED ·Phase: PHASE1
-
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
NCT04072458 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
NCT04547062 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety Study in Patients With Chronic Lymphocytic Leukemia
NCT00283101 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
NCT04239157 ·Status: RECRUITING ·Phase: PHASE2